Sanofi, Regeneron Allowed to Sell Cholesterol Drug

Feb 09, 2017

A federal appeals court said Regeneron Pharmaceuticals Inc. and Sanofi SA can continue selling their cholesterol drug, Praluent, while they appeal the order, according to a Reuters article.

A judge previously blocked sales of the drug after Amgen won a trial wherein it accused them of patent infringement. The order would have taken effect on Feb. 21.

Regeneron general counsel Joseph LaRosa said in a statement the company would continue to defend its case through the appeal process.

Read the full story